THE WOODLANDS, Texas--(BUSINESS WIRE)--Aug. 3, 2006--Repros Therapeutics Inc. (Nasdaq:RPRX) (PCX:RPRX) today reported financial results for the three-months and six-months ended June 30, 2006 and provided an update on clinical development programs. During the second quarter 2006, shareholders of the Company approved a name change from Zonagen, Inc. to Repros Therapeutics Inc., to reflect the Company’s new product development focus.
